Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018

Meet the future of antibody-based immuno-oncology drugs (May 16, 2018)

LUND, Sweden, May 16, 2018 /PRNewswire/ --

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, invites analysts, investors and media to its capital markets day in Stockholm on Tuesday May 29, 2018. 

The program will start at 2:00 pm CEST, with registration from 1:00 pm CEST and will end with networking at 5:00 pm CEST. The event will take place at GT30, room Turbinen, Grev Turegatan 30 in Stockholm. The event will include presentations by Professor Carl Borrebaeck, co-founder of Alligator, Per Norlén, CEO, as well as representatives from the company management team. The presentations will give an update on the Alligator project pipeline, including a discussion on the future development of immuno-oncology antibodies. Moderator for the day will be business journalist Charlotte Stjerngren. 



The event will be conducted in English and there will be a simultaneous live conference call and webcast for those unable to attend in person. The webcast will be available to view on Alligator's website www.alligatorbioscience.com and a recording will be made available shortly after the event.  

Please register by May 24, 2018 via email to:
anmalan@alligatorbioscience.com with the subject "CMD May 29". 

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications 
Phone: +46-46-286-44-95 
E-mail: cecilia.hofvander@alligatorbioscience.com 

The information was submitted for publication, through the agency of the contact person set out above, at 10:30 a.m. CEST on May 16, 2018. 

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com

Read the complete invitation in the attached pdf. 

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/alligator-bioscience/r/invitation-to-alligator-bioscience-capital-markets-day-in-stockholm-on-may-29--2018,c2521894

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/invitation-to-alligator-bioscience-capital-markets-day-in-stockholm-on-may-29-2018-300649379.html

SOURCE Alligator Bioscience

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Networking,Internet,Management,CEO/CFO,Pro AV,Management,Presentors,Business,PDF,Business Issues,Internet Media,Presentation,email, webcast, Inc.,Business,Email,
Related Sites: Digital Producer ,   Digital Webcast ,   Presentation Master ,   DMN Newswire ,   itbusinessnet.com ,   IBN - Business ,   IBN - Networking ,   IBN - Internet ,   BN - Webcast ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: DMN Newsletter ,   CMN Newsletter ,   Streamline Newsletter ,   KNews Newsletter ,   Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved